CTIS.eu › Cities › France › Paris
Paris
France
2,322 total trials
1,025 recruiting
Filter these 2,322 trials by phase, condition, sponsor and more.
Open in Search →
2022-502362-24-00
4
2026-06-30
Erosive osteoarthritis
2025-522339-32-00
9
2026-06-30
Neoplasm malignant
2022-502910-10-00
7
2026-06-26
Propionic Acidemia
2025-522267-15-00
10
2026-06-24
Relapsed/refractory B-cell Acute Lymphoblastic Leukemia
2025-520565-51-00
5
2026-06-23
small cell lung cancer
2025-524894-17-00
10
2026-06-22
Neovascular age-related macular degeneration (NVAMD)
2025-523579-47-00
4
2026-06-19
moderate to severe rheumatoid arthritis (RA)
2025-522435-33-00
5
2026-06-17
Hemophilia A
2025-522643-18-00
5
2026-06-16
Stage I NSCLC
2023-505200-33-00
5
2026-06-15
Multiple myeloma
2025-523005-15-00
9
2026-06-15
Non-Hodgkin Lymphoma
2025-524843-11-00
4
2026-06-15
Non-Small Cell Lung Cancer
2025-523117-28-00
4
2026-06-12
Relapsed or Refractory Multiple Myeloma
2025-523576-23-00
5
2026-06-12
Unresectable Stage III non-small cell lung cancer without progression
2025-523443-35-00
5
2026-06-11
Persistent Corneal Epithelial Defect (PCED)
2025-523586-18-00
5
2026-06-11
Non-Small Cell Lung Cancer
2025-524316-11-00
5
2026-06-11
Primary Progressive Multiple Sclerosis (PPMS)
2025-523521-18-00
5
2026-06-09
Metastatic Colorectal Cancer
2025-522618-22-00
5
2026-06-05
Treatment of moderate to severe glabellar lines
2025-524056-63-00
1
2026-06-05
microsatellite instability high/mismatch repair deficient (MSI-H/dMMR)
2025-524408-30-01
5
2026-06-05
Metastatic hormone-sensitive prostate cancer
2025-523425-17-00
4
2026-06-03
Proteinuric kidney diseases
2025-523567-38-00
4
2026-06-02
locally advanced or metastatic NSCLC
2024-519994-20-00
5
2026-06-01
Agitation Associated with Alzheimer’s Disease
Showing 241–264 of 2,322 trials